Ventyx Biosciences Reports P-II Trial Results of VTX002 for Moderate-to-Severely Active Ulcerative Colitis
Shots:
- The P-II trial evaluating VTX002 (30 & 60mg, qd) vs PBO in patients with mod. to severely active UC, showed that 28% of patients on 60mg dose & 24% on 30mg dose achieved the 1EPs of clinical remission at 13wk. over 11% on PBO; 29% & 21% achieved the 1EPs of complete endoscopic remission (Mayo endoscopic subscore of 0) vs 7% in PBO
- Dose response was observed b/w both doses of VTX002 across key EPs thus providing evidence of clinical benefit with a greater mean reduction in absolute lymphocyte count achieved with the 60mg dose relative to the 30mg dose
- The therapy was well tolerated in both dose cohorts with no treatment-related serious AEs & no cases of macular edema were seen. The results will be presented at a future medical meeting
Ref: Globenewswire | Image: Ventyx
Related News:- AltruBio Receives the US FDA’s IND Clearance to Initiate a P-II Clinical Trial of ALTB-268 for Ulcerative Colitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
